...
首页> 外文期刊>Journal of pharmaceutical sciences. >High-throughput determination of the free fraction of drugs strongly bound to plasma proteins.
【24h】

High-throughput determination of the free fraction of drugs strongly bound to plasma proteins.

机译:高通量测定与血浆蛋白强烈结合的药物游离部分。

获取原文
获取原文并翻译 | 示例
           

摘要

Quantification of protein binding of new chemical entities is an important early screening step during drug discovery and is of fundamental interest for the estimation of safety margins during drug development. In this publication, we describe the development of a new high-throughput assay for the determination of the free drug fraction in plasma (fu). The new technique is an enhancement of the previously published erythrocytes partition method. It is based on the distribution of drugs between plasma water, plasma proteins, and solid-supported lipid membranes (Transil). The execution of protein binding studies by partitioning is dramatically simplified by substituting erythrocytes with commercially available Transil beads, and makes the method particularly suitable for high-throughput studies. Eight Bayer compounds from different compound classes covering a wide range of lipophilicities (log P = 1.9-5.6) and fu values (0.018-35%) were selected for validation of the assay. The results obtained by the new method and by either the erythrocytes partitioning technique or more conventional methods (ultrafiltration and equilibrium dialysis) are identical, confirming that the new method produces valid results even for drugs that are strongly bound to plasma proteins. Precision and accuracy of the data in the cases of very low and high fu values are comparable, indicating that the method is especially suited for highly lipophilic drugs that tend to adsorb to surfaces compared with other methods, like ultrafiltration or equilibrium dialysis, that may produce biased data. The method is also useful for the determination of binding parameters and the pH dependence of fu. In summary, this assay is well suited for high-throughput determination of protein binding during drug discovery and for extended protein binding studies during drug development.
机译:对新化学实体的蛋白质结合进行定量分析是药物开发过程中重要的早期筛选步骤,并且对于评估药物开发过程中的安全范围至关重要。在本出版物中,我们描述了一种新的高通量测定法的发展,该测定法可用于测定血浆中的游离药物组分(fu)。新技术是对以前公开的红细胞分配方法的增强。它基于药物在血浆水,血浆蛋白和固体支持的脂质膜(Transil)之间的分布。通过将红细胞替换为可商购的Transil珠子,可以显着简化通过分区进行蛋白质结合研究的过程,这使该方法特别适合于高通量研究。选择了来自不同化合物类别的八种拜耳化合物,这些化合物涵盖了广泛的亲脂性(log P = 1.9-5.6)和fu值(0.018-35%),以用于测定验证。通过新方法以及通过红细胞分配技术或更常规的方法(超滤和平衡透析)获得的结果是相同的,证实了该新方法即使对于与血浆蛋白牢固结合的药物也能产生有效的结果。在非常低和高fu值的情况下,数据的精确度和准确性是可比的,这表明该方法特别适用于与其他方法(例如超滤或平衡透析)相比可能吸附到表面的高度亲脂性药物有偏见的数据。该方法还可用于测定fu的结合参数和pH依赖性。总而言之,该测定非常适合在药物发现过程中高通量测定蛋白质结合,以及在药物开发过程中进行扩展的蛋白质结合研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号